Examining the role of hypoxia in hereditary hemorrhagic telangiectasia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the influence of hypoxic induced factors on patients with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder characterized by systemic vascular malformations. It aims to understand how environmental factors, particularly hypoxia, may contribute to the disease's progression and severity. The study will analyze patients diagnosed with HHT to explore the relationship between hypoxia and angiogenesis, which is crucial for understanding the underlying mechanisms of the condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosed HHT (genetic testing and/ or fulfill at least 3 Curacao Criteria)
* older than 17 years
* ability to consent

Exclusion Criteria:

* if inclusion Criteria are not met

Where it's running

• University Hospital Essen
  Essen, North Rhine-Westphalia, Germany Recruiting

Study contacts

• Principal investigator: Freya Droege, MD — University hospital Essen Otorhinolaryngology, Hufelandstr. 55, 45147 Essen, Germany
• Study coordinator: Freya Droege, MD
• Email: freya.droege@uk-essen.de
• Phone: 0049201 723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Body donation in HHT

  This study tests whether donated human tissue with and without vascular malformations from people with hereditary hemorrhagic telangiectasia can be analyzed to better understand the disease.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07826845

• Engasertib for moderate to severe HHT: see if daily 40 mg helps with nosebleeds

  This trial tests whether taking engasertib once daily for 28 weeks reduces nosebleed frequency in adults with hereditary hemorrhagic telangiectasia compared with placebo.

  Recruiting at 4 sites Phase 3 Vaderis Therapeutics AG · Chicago, Illinois and 3 other locations · NCT07743671

• DIAG723 in Adults With HHT

  A first-in-human study tests DIAG723 versus placebo in adults with hereditary hemorrhagic telangiectasia to see if it is safe and possibly helpful.

  Recruiting at 3 sites Phase 1/2 Diagonal Therapeutics, Inc. · Camperdown, New South Wales and 10 other locations · NCT07623525

• Registry for patients with Hereditary Hemorrhagic Telangiectasia

  This study is collecting information from people with Hereditary Hemorrhagic Telangiectasia to better understand the condition and help improve treatments in the future.

  Recruiting at 16 sites Cure HHT · Birmingham, Alabama and 15 other locations · NCT06259292

• Evaluating Antiplatelet and Anticoagulation Therapy in Hereditary Hemorrhagic Telangiectasia

  This study is testing how well people with Hereditary Hemorrhagic Telangiectasia can handle new blood-thinning treatments compared to not using them, to find out which ones work best for them.

  Recruiting at 13 sites University Hospital, Clermont-Ferrand · Angers and 17 other locations · NCT05641142

• Using nintedanib to treat nosebleeds in patients with hereditary hemorrhagic telangiectasia

  This study is testing if the medication nintedanib can help reduce the number and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia.

  Recruiting at 2 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Bron and 2 other locations · NCT04976036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.